Chavda, V. P., Ajabiya, J., Teli, D., Bojarska, J., & Apostolopoulos, V. (2022). Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini-review. Molecules, 27(13), 4315. https://doi.org/10.3390/molecules27134315

Karagiannis, T., Avgerinos, I., Liakos, A., Del Prato, S., Matthews, D. R., Tsapas, A., & Bekiari, E. (2022). Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: A systematic review and meta-analysis. Diabetologia, 65, 1251–1261.
https://doi.org/10.1007/s00125-022-05715-4

Min, T., & Bain, S. C. (2020). The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials. Diabetes Therapy, 11(9), 1941–1957. https://doi.org/10.1007/s13300-020-00981-0

Sokary, S., & Bawadi, H. (2025). The promise of tirzepatide: A narrative review of metabolic benefits. Primary Care Diabetes, 19(3), 229–237. https://doi.org/10.1016/j.pcd.2025.03.008